Hypothetical Concerns

I was greatly heartened by David Horrobin's article "Discouraging Hypotheses Slows Progress" [The Scientist, Nov. 26, 1990, page 13]. For 10 years I have been attempting to publish what amounts to a unified hypothesis of the evolutionary development of intermediary metabolic cell growth control and, in particular, how it relates to cellular differentiation and cancer cell growth. Of course, a full testing of the hypothesis would be nothing short of a Manhattan Project-sized undertaking. However

Written byGregory Bambeck
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Although I graduated at the top of my class, and in the top 1 percent worldwide, this inability to publish a unifying theory has not only had detrimental consequences on my career, but also casts serious aspersions upon both the recognized scientific leadership and the hierarchical bureaucratic publication mechanism in the medical, biomolecular, and allied sciences. It is nothing short of ethical scientific crime when United States patents can be granted, based upon a theory that can't even be published. How much "proof in the pudding" is required to couple theory and application to publication?

I find Horrobin's efforts to be laudable and downright heroic. We theoreticians tire of receiving blanket rejections by publication staff members who do not even permit our work to be submitted to the review process. There is nothing more demeaning to a qualified professional than to be rejected from peer review consideration by the publication ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies